The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $13.42

Today's change0.00 0.00%
Updated October 16 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $13.42

Today's change0.00 0.00%
Updated October 16 4:00 PM -4GMT. Delayed by at least 15 minutes.

Merrimack Pharmaceuticals Inc closed at (U.S.)$13.42.

Over the last five days, shares have gained 2.44%, but are down 67.11% for the last year to date. Shares have underperformed the S&P 500 by 92.85% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $13.42
  • High--
  • Low--
  • Bid / Ask(U.S.) $10.19 / (U.S.) $15.18
  • YTD % change-67.11%
  • Volume0
  • Average volume (10-day)273,270
  • Average volume (1-month)286,882
  • Average volume (3-month)232,496
  • 52-week range(U.S.) $11.30 to (U.S.) $67.90
  • Beta1.75
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward0.40×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$9.21
Updated October 16 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-137.45%

Although this company's net profit margin is negative, it is above the industry average and implies that Merrimack Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.03%Sector:HealthcareIndustry:Biotechnology

Latest Company News

    No News Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue----6128
Total other revenue--------
Total revenue006128
Gross profit----5827
Total cost of revenue----31
Total operating expense35278852
Selling / general / administrative1562418
Research & development20225532
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)----51
Other operating expenses, total--------
Operating income-35-27-26-24
Interest income (expense), net non-operating-27-2-7-7
Gain (loss) on sale of assets2------
Other--------
Income before tax-60-29-34-30
Income after tax-30-29-34-30
Income tax, total-30------
Net income512-30-32-30
Total adjustments to net income--------
Net income before extra. items-29-29-32-30
Minority interest1010
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-29-29-32-30
Inc. avail. to common incl. extra. items512-30-32-30
Diluted net income512-30-32-30
Dilution adjustment--000
Diluted weighted average shares13131313
Diluted EPS excluding extraordinary itemsvalue per share-2.18-2.20-2.50-2.33
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-2.27-2.20-2.11-2.26